You are now searching


New York BBB Wise Giving Report for
New York Blood Center

A BBB Accredited charity


  • Meets all standards

Expiration Date:
New York Blood Center
310 East 67th Street
New York, NY 10065
Year, State Incorporated:
1959, New York
Stated Purpose:
" The organization has fulfilled a lifesaving mission to provide the highest quality blood and stem cell products, donor and patient medicals services, and innovative research. "

Evaluation Conclusions

New York Blood Center (NYBC) meets the 20 Standards for Charity Accountability.


Blood Services: Through the combined efforts of our geographic blood services operations, approximately 2,000 units of blood products are collected each day and distributed to hospitals and medical centers throughout New York City, Long Island, the Hudson Valley, New Jersey, Connecticut, and Pennsylvania. NYBC’s blood products help meet the daily transfusion needs of cancer and surgery patients, accident and burn victims, newborns and mothers delivering babies, AIDS and sickle cell anemia patients, organ transplant recipients, and many others. Medical Programs and Services: With a well-established, growing medical agenda, we provide education to patients, physicians, and researchers and manage transfusion services for hospital partners. • Clinical Services provides more than 8,500 highly specialized patient care procedures each year, and our Hemophilia Services Program ensures that hundreds of local patients with hemophilia and other blood clotting disorders have access to the clotting factors they need to survive 24 hours a day, seven days a week. • Special Donor and Community Health Services includes outreach initiatives such as the Cardiovascular Disease Risk Screening project and Hereditary Hemochromatosis Phlebotomy Program. • Bone Marrow Registry Program works in conjunction with the Be The Match Registry®, operated by the National Marrow Donor Program, to provide bone marrow grafts for transplantation to patients suffering from leukemia and other life threatening diseases. • Professional Education sponsors an Accreditation Council for Graduate Medical Education (ACGME) Transfusion Medicine Fellowship Program. • Cellular Therapy Laboratory is a pioneer in personalized medicine. Bone marrow transplantation can cure blood malignancies like leukemia and genetic disorders such as sickle cell disease. Each year, the laboratory processes, cryopreserves, stores, and releases for transplantation hundreds of unique products for individual patients. • PreciseMatch® Program matches donated blood with patients in need, going beyond typical A, B, and O blood typing to ensure our multicultural patient population has access to a more diverse supply of blood products. Operations and Manufacturing includes all blood testing laboratories; provides antigen-negative red cells; educates NYBC fellows, visiting physicians, and other visitors; and serves hospitals in our regions as well as national and international laboratories. The laboratories maintained within Operations and Manufacturing perform quality control on our blood products to ensure their safety, quality, integrity, purity, and potency. The Frozen Blood Laboratory is an integral part of NYBC, providing rare products to patients in need of highly categorized antigen negative blood. The Laboratory of Immunohematology and Genomics, under the leadership of Director Connie Westhoff, SBB, PhD, identifies new blood group antigens and supports patient needs. Lindsley F. Kimball Research Institute’s (LFKRI) world-renowned scientists lead some of the most innovative hematology and transfusion medicine research in the world. Our research has paved the way for new blood-related products, techniques, and therapies as well as numerous landmark patents. LFKRI is home to nearly 100 scientists and staff in more than a dozen laboratories working to discover life-saving solutions that result in improved patient outcomes, breakthrough cures, and advanced treatment for an array of blood-related diseases. Our laboratories develop novel approaches to treating infectious and blood-borne illnesses, immune system disorders, and red cell and platelet diseases. We continue to research global health threats and work toward developing treatments for malaria, sickle cell disease, and severe acute respiratory syndrome (SARS). From the discovery of the first HIV-fusion inhibitor to treat AIDS to the development of a solvent detergent which inactivates viruses in blood plasma, LFKRI has made an indelible mark on transfusion medicine. National Cord Blood Program (NCBP): With over 60,000 donations and more than 4,500 patients transplanted at 220-plus transplant centers worldwide, NCBP advances the use of umbilical cord blood as a potential treatment for many diseases, including acute leukemia, lymphoma, sickle cell anemia, and other lethal diseases of the blood or immune system. Our work helps patients whose only chance of survival is a transplant that replaces the diseased cells in their bone marrow with healthy cells. In addition to clinical therapies, NCBP makes cord blood units (CBUs) available for stem cell research. Research-use CBUs are donated by the mother after being notified that the unit does not meet criteria for transplantation. Between 2011 and 2012, NYBC provided over 6,000 research-use CBUs to investigators at key research centers such as Memorial Sloan-Kettering Cancer Center, Columbia University, Tufts University, Mount Sinai School of Medicine, University of Minnesota, University of Miami, and Walter Reed Army Institute of Research.


Chief Executive Officer:
Dr. Christopher D. Hillyer, Chief Executive Officer
Chair of the Board:
Howard P. Milstein
Chair's Profession / Business Affiliation:
Emigrant Savings Bank, Co-Chairman
Board Size:
Paid Staff Size:

*Compensation includes annual salary and, if applicable, benefit plans, expense accounts, and other allowances.

Fund Raising

Method(s) Used:

Direct mail appeals, invitations to fund raising events, grant proposals, internet, Event Sponsorship
Fund raising costs were 3.3% of related contributions. (Related contributions, which totaled $12,185,000, are donations received as a result of fund raising activities.)

Tax Status

This organization is tax-exempt under section 501(c)(3) of the Internal Revenue Code. It is eligible to receive contributions deductible as charitable donations for federal income tax purposes.


The following information is based on NYBC's Audited Financial Statement for the fiscal year ended March 31, 2012.

Source of Funds  

Whole Blood and Plasma Derivatives


National Institutes of Health and Other Government Grants




Other Research grants and contracts






Total Income


Program Expenses  

Blood Services


Medical Services


Research Program

Total Program Expenses:
Fund Raising Expenses
Administrative Expenses

Total expenses

Expenses in Excess of Income




Uses of Funds as a % of Total Expenses

Programs: 91%  Fund Raising: %  Administrative 9% 
Roll the cursor over the pie chart to see the dollar amounts.

Beginning net assets $387,783,000
Ending net assets 380,389,000
Total liabilities 79,107,000

Total assets



A copy of this report has been shared with the organization prior to publication. It is not intended to recommend or deprecate, and is furnished solely to assist you in exercising your own judgment. The name Better Business Bureau is a registered service mark of the Council of Better Business Bureaus, Inc.

This report is not to be used for fundraising or promotional purposes and may not be reproduced or distributed in whole or in part.